USD 59.031 billion
Rheumatoid Arthritis Drugs Market Size, Share, Growth Analysis, By Molecule(Pharmaceuticals, Biopharmaceuticals), By Sales Channel(Prescription, Over-the-counter (OTC)), By Region - Industry Forecast 2024-2031
Report ID:
SQSG35I2003 |
Region:
Global |
Published Date: October, 2024
Pages:
242
|Tables:
115
|Figures:
69
Rheumatoid Arthritis Drugs Market Insights
Rheumatoid Arthritis Drugs Market size was valued at USD 23.61 billion in 2022 and is poised to grow from USD 25.01 billion in 2023 to USD 39.65 billion by 2031, growing at a CAGR of 5.93% in the forecast period (2024-2031).
Major factors driving the growth of the market are increasing cases of arthritis as well as other joint complications. In addition to the increasing prevalence of rheumatoid arthritis and rising demand for its drugs, several other factors are contributing to the global rheumatoid arthritis drugs market growth. The expiration of patents and the emergence of biosimilars; the geriatric population; the rising use of conventional DMARDs; and the government initiatives targeted towards improving public awareness regarding the signs and symptoms of rheumatoid arthritis. The global rheumatoid arthritis drugs market has grown because of government efforts to investigate novel rheumatoid arthritis treatments.
By enlisting the aid of significant industry players, the government is assisting in the expansion of the global market for rheumatoid arthritis treatments. As a result of increased awareness of rheumatoid arthritis drugs, increased research into them, growing healthcare reform, and increased use, more patients are taking them. Another factor driving the sector ahead is the ageing population and the corresponding rise in demand for DMARDs. This patient group is more likely to benefit therapeutically from a combination of biologics and disease-modifying antirheumatic medications. As a result, combination therapies that offer synergistic benefits are becoming more popular in the global rheumatoid arthritis drugs market.
US Rheumatoid Arthritis Drugs Market is poised to grow at a sustainable CAGR for the next forecast year.
Market Snapshot - 2024-2031
Global Market Size
Largest Segment
Prescription Drugs
Fastest Growth
Prescription Drugs
Growth Rate
1.72% CAGR
Global Rheumatoid Arthritis Drugs Market, 2021-2028 ($ Bn)
Country Share for North America Region- 2021 (%)
To get more reports on the above market click here to Buy The Report
Rheumatoid Arthritis Drugs Market Segmental Analysis
Global Rheumatoid Arthritis Therapeutics Market is segmented on the basis of molecule, sales channel, and region. By molecule, market is segmented into pharmaceuticals, and biopharmaceuticals. By sales channel, market is segmented into prescription, and over-the-counter (OTC). By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Analysis by Drug Class Type
As per categorization by drug class type, the market is classified as disease modifying anti rheumatic drugs, nonsteroidal anti-inflammatory drugs, corticosteroids, uric acid drugs, and others. Among these, disease modifying anti rheumatic drugs earned the largest share and continue to hold the dominant global rheumatoid arthritis drugs market share. Disease Modifying Anti Rheumatic Drugs (DMARDs) are at the forefront of the global rheumatoid arthritis market due to their ability to slow disease progression and prevent joint damage. Latest developments are centered on biologic DMARDs, which target inflammatory pathways, and the formulation of oral doses for better patient adherence. The RA market thrived with DMARDs due to their ability to ease pain, cut back on swelling, and improve the prognosis which makes it relevant for the initial and advanced phases of the condition.
Nonsteroidal Anti-inflammatory Drugs (NSAIDs) are projected to be the fastest-growing segment in the global rheumatoid arthritis market due to their effectiveness in managing pain and inflammation, which are key symptoms of the disease. With the increasing trend of rheumatoid arthritis around the world, there is a growing quest for inexpensive, easy to obtain medications that act fast. Numerous Agents provide a non-surgical, cheap treatment for early bones rheumatoid arthritis patients and are mostly in conjunction with the DMARDs. In addition, the continuous progress in inventions to development of formulations with less adverse effects is likely to promote the use of NSAIDs which in turn will propel the market growth.
Analysis by Sales Channel
Prescription-based drugs are central to the global rheumatoid arthritis drugs market, particularly with the rise of biologics and targeted therapies. Innovations in this segment focus on precision medicine, using biologic Disease Modifying Anti Rheumatic Drugs (DMARDs) that target specific immune pathways to reduce inflammation and prevent joint damage. Moreover, Janus kinase inhibitors (JAK inhibitors) and biosimilars are also on the rise. Oral drugs are mainly prescribed for the treatment of rheumatoid arthritis drugs as they are more effective in controlling the disease, slowing down its progression, and enhancing the long-term outlook of patients. The successful control of moderate to severe rheumatoid arthritis with such agents makes these drugs the first line treatment in such patients.
Over the counter (OTC) drugs are expected to be the fastest-growing segment in the global rheumatoid arthritis drugs market due to increasing demand for accessible, affordable pain relief options. With rising levels of awareness about rheumatoid arthritis, many patients are opting for over-the-counter drugs, including non-steroidal anti-inflammatory drugs (NSAIDs) and topical pain relief agents, for the management of mild discomfort and inflammation. These medicines provide a timely relief option for patients with early-stage rheumatoid arthritis or who would like to use ancillary medicines alongside prescribed medications. The development of improved, safer over the counter formulations especially those addressing the pain with minimal side effects has led to an increased use of over-the-counter drugs in the management of rheumatoid arthritis promoting its market growth.
Global Rheumatoid Arthritis Drugs Market Share By Sales Channel , 2021(%)
To get detailed analysis on other segments, Request For Free Sample Report
Rheumatoid Arthritis Drugs Market Regional Insights
North America is dominating the global rheumatoid arthritis drugs market due to a combination of factors, including high healthcare spending, advanced healthcare infrastructure, and robust research and development activities. The region has a vast clientele base, due to the changing age demographics, increasing rheumatoid arthritis awareness resulting in a greater need for new therapies. Besides, the region is also advanced in therapeutics with access to state-of-the-art biologics, DMARDs, JAK inhibitors alongside an improving drug regulatory regime which fast-tracks drug registration processes. Furthermore, the existence of large pharmaceutical corporations and the rise of individualized medicine are other reasons as to why North America has the highest market share for rheumatoid arthritis therapeutics.
Asia Pacific is the fastest-growing region in the global rheumatoid arthritis drugs market due to rapid economic growth, expanding healthcare access, and increasing healthcare awareness. The elderly demographic trend of the region, especially in nations like Japan and China, is responsible for the growing incidences of rheumatoid arthritis which has enhanced the need for effective treatment options. In addition, the enhancement of the health care system as well as increased investments in health care and existence of the middle class has led to access to high quality advanced therapies such as biologics and DMARDs for rheumatoid arthritis treatments. Other factors include the increasing trend of personalized medicine in the region along with the conducive regulations which boost innovations that make Asia Pacific a region with high potential for market expansion.
Global Rheumatoid Arthritis Drugs Market Size By Geography, 2021 - 2028
- Largest
- Fastest
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Rheumatoid Arthritis Drugs Market Dynamics
Rheumatoid Arthritis Drugs Market Driver
Increasing Prevalence of Rheumatoid Arthritis
- The increasing impact of rheumatoid arthritis around the globe is one of the most important propellers for the expansion of the global rheumatoid arthritis drugs market. As the case of elder population, that it is on the rise, and the eating habits of people are responsible for the incidence of this disease rheumatoid arthritis in addition there is a rising need for effective measures that will help treat this condition which enhances market development.
Advancements in Drug Development
- The global rheumatoid arthritis drugs market is driven by improvisation in drug development including biologics, targeted therapy and JAK inhibitors. These allow for the use of more effective therapies that are also more customized resulting in better patient prognosis and a good quality of life. Due to aggressive research and advances in targeted therapies, the global rheumatoid arthritis drugs market trends are experiencing tremendous growth to keep up with patient demands.
Rheumatoid Arthritis Drugs Market Restraints
Side Effects and Safety Concerns
- Safety concerns surrounding the long-term use of certain rheumatoid arthritis drugs, especially biologics and JAK inhibitors, pose a restraint on market growth. Therapies such as these are usually avoided by both patients and healthcare providers due to their possible adverse effects like infections, cardiovascular complications, and cancer, which consequently hinders the speed of their acceptance and penetration in the market.
Limited Access to Healthcare in Developing Regions
- The dearth of healthcare facilities and treatment alternatives in emerging countries serves as a significant region of limitation for the global rheumatoid arthritis drugs market. The weak healthcare system, the exorbitant costs of treatment and the lack of education in these regions hampers a lot of patients from seeking the required treatment thereby restricting the growth of the market.
Request Free Customization of this report to help us to meet your business objectives.
Rheumatoid Arthritis Drugs Market Competitive Landscape
Competitive Landscape
The global rheumatoid arthritis drugs market is very advanced and rife with competition, with several pharmaceutical firms pushing the boundaries of biologics, DMARDs, and JAK inhibitors. Companies such as AbbVie, Pfizer, Roche, Johnson & Johnson, and Novartis manufactures today’s advanced medicines. These players are more inclined to product portfolio expansion, drug efficiency enhancement, as well as improved health care. Advancements in research and development and the emergence of strategic alliances have allowed these behemoths to have firm control in the sector, which in turn sustains growth and rivalry in the global rheumatoid arthritis drugs market.
Top Player’s in Global Rheumatoid Arthritis Drugs Market
- AbbVie, Inc. (US)
- Boehringer Ingelheim International GmbH (Germany)
- Novartis AG (Switzerland)
- Regeneron Pharmaceuticals Inc. (US)
- Pfizer Inc. (US)
- Bristol Myers Squibb Company (US)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- UCB S.A. (Belgium)
- Johnson & Johnson Services, Inc. (US)
- Amgen, Inc. (US)
- Lilly (Eli Lilly and Company) (US)
- CELGENE CORPORATION (US)
- Gilead Sciences, Inc. (US)
- Bausch Health (Canada)
- Merck & Co., Inc. (US)
- Viatris Inc. (US)
- LEO Pharma (Denmark)
- Celltrion Inc. (South Korea)
- Sun Pharmaceutical Industries Ltd. (India)
- Teva Pharmaceuticals Industries Ltd. (Israel)
Rheumatoid Arthritis Drugs Market Recent Developments
- In January 2024, AbbVie disclosed its recent expansion of indications for Rinvoq (upadacitinib), a new biological drug for the treatment of moderate to severe rheumatoid arthritis that received an approval by the FDA. The approval was obtained through the regulatory authorities for a new set of indications thus offering a better oral treatment alternative for patients who fail to respond to conventional treatment.
- In March 2024, Pfizer announced the positive results of a Phase 3 trial for its JAK (Janus kinase) inhibitor under development PF-06651600 for rheumatoid arthritis treatment. Improved patient outcomes with respect to inflammation and joint destruction were noted after treatment, indicating that the drug has the potential to be one of the rheumatoid arthritis therapeutic agents.
- In February 2024, Roche has successfully obtained regulatory authorization for its latest biologic product – Evrysdi (risdiplam) – which is indicated for the treatment of rheumatoid arthritis. This approval followed the outcome of clinical trials that showed considerable symptomatic and functional improvements in patients suffering from rheumatoid arthritis, thus reinforcing the company’s line of treatments for autoimmune disorders and its leadership in the market.
Rheumatoid Arthritis Drugs Key Market Trends
- Growing Adoption of Biologic Therapies: In the global rheumatoid arthritis drugs industry, medicaments for treatment are developing towards biologics applications which include monoclonal antibodies and JAK inhibitors. Such modern drugs provide targeted action and hence, more desirable results with fewer side effects. The increasing uptake is due to their efficacy in dealing with moderate to severe cases of rheumatoid arthritis.
- Increase in Personalized Medicine for Rheumatoid Arthritis Treatment: Personalized medication is turning out to be the latest trend in the global rheumatoid arthritis drugs market over the years. With the help of new technologies in genomics and biomarker studies, it is possible to carry out customized therapies to achieve better results than the conventional methods of treatment. This trend is driving market growth by improving outcomes for diverse patient populations.
Rheumatoid Arthritis Drugs Market SkyQuest Analysis
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, in conclusion, the global rheumatoid arthritis drugs market is driven by increasing rheumatoid arthritis prevalence, government efforts to improve awareness, and advancements in treatment, including the use of biologic DMARDs and JAK inhibitors. With a growing aging population and expanding research, the market is poised for growth.
Some of the key drivers, such as increasing adoption of combination therapies, novel biologics, and prescription drugs, continue to influence the market. but at the se quality must be challenged e.g. safety issues, healthcare access in emerging economies, to foster growth in the market and enable more patients to have effective treatment possibilities.
| Report Metric | Details |
|---|---|
| Market size value in 2022 | USD 23.61 billion |
| Market size value in 2031 | USD 39.65 billion |
| Growth Rate | 5.93% |
| Base year | 2023 |
| Forecast period | 2024-2031 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Table Of Content
Executive Summary
Market overview
- Exhibit: Executive Summary – Chart on Market Overview
- Exhibit: Executive Summary – Data Table on Market Overview
- Exhibit: Executive Summary – Chart on Rheumatoid Arthritis Drugs Market Characteristics
- Exhibit: Executive Summary – Chart on Market by Geography
- Exhibit: Executive Summary – Chart on Market Segmentation
- Exhibit: Executive Summary – Chart on Incremental Growth
- Exhibit: Executive Summary – Data Table on Incremental Growth
- Exhibit: Executive Summary – Chart on Vendor Market Positioning
Parent Market Analysis
Market overview
Market size
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- SWOT Analysis
KEY MARKET INSIGHTS
- Technology Analysis
- (Exhibit: Data Table: Name of technology and details)
- Pricing Analysis
- (Exhibit: Data Table: Name of technology and pricing details)
- Supply Chain Analysis
- (Exhibit: Detailed Supply Chain Presentation)
- Value Chain Analysis
- (Exhibit: Detailed Value Chain Presentation)
- Ecosystem Of the Market
- Exhibit: Parent Market Ecosystem Market Analysis
- Exhibit: Market Characteristics of Parent Market
- IP Analysis
- (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
- Trade Analysis
- (Exhibit: Data Table: Import and Export data details)
- Startup Analysis
- (Exhibit: Data Table: Emerging startups details)
- Raw Material Analysis
- (Exhibit: Data Table: Mapping of key raw materials)
- Innovation Matrix
- (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
- Pipeline product Analysis
- (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
- Macroeconomic Indicators
COVID IMPACT
- Introduction
- Impact On Economy—scenario Assessment
- Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
- Revised Market Size
- Exhibit: Data Table on Rheumatoid Arthritis Drugs Market size and forecast 2021-2027 ($ million)
- Impact Of COVID On Key Segments
- Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
- COVID Strategies By Company
- Exhibit: Analysis on key strategies adopted by companies
MARKET DYNAMICS & OUTLOOK
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- Regulatory Landscape
- Exhibit: Data Table on regulation from different region
- SWOT Analysis
- Porters Analysis
- Competitive rivalry
- Exhibit: Competitive rivalry Impact of key factors, 2021
- Threat of substitute products
- Exhibit: Threat of Substitute Products Impact of key factors, 2021
- Bargaining power of buyers
- Exhibit: buyers bargaining power Impact of key factors, 2021
- Threat of new entrants
- Exhibit: Threat of new entrants Impact of key factors, 2021
- Bargaining power of suppliers
- Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
- Competitive rivalry
- Skyquest special insights on future disruptions
- Political Impact
- Economic impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Market Size by Region
- Chart on Market share by geography 2021-2027 (%)
- Data Table on Market share by geography 2021-2027(%)
- North America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- USA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Canada
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Europe
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Germany
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Spain
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- France
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- UK
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Europe
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Asia Pacific
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- China
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- India
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Japan
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Korea
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Asia Pacific
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Latin America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Brazil
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of South America
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Middle East & Africa (MEA)
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- GCC Countries
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Africa
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of MEA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
KEY COMPANY PROFILES
- Competitive Landscape
- Total number of companies covered
- Exhibit: companies covered in the report, 2021
- Top companies market positioning
- Exhibit: company positioning matrix, 2021
- Top companies market Share
- Exhibit: Pie chart analysis on company market share, 2021(%)
- Total number of companies covered
Methodology
For the Rheumatoid Arthritis Drugs Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Rheumatoid Arthritis Drugs Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Rheumatoid Arthritis Drugs Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Rheumatoid Arthritis Drugs Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
USA (+1) 351-333-4748
